# Genmab clinical trial developments

> Developing situation record from CLSTR: https://clstr.news/situations/genmab-clinical-trial-developments
> Updated: 2026-10-28T14:10:34.000Z. Sources: 8. Developments: 2.

Genmab A/S has reported positive clinical trial results for multiple investigational treatments. Initial reports highlighted Phase 1/2 data for the antibody-drug conjugate rinatabart sesutecan (Rina-S) in treating platinum-resistant ovarian cancer. The RAINFOL-01 trial showed a confirmed objective response rate of 45.9% and a median progression-free survival of 9.5 months.

Subsequent developments included successful Phase 3 results for the bispecific antibody petosemtamab in the LiGeR-HN1 trial. When combined with pembrolizumab, petosemtamab met primary endpoints for first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma, reducing the risk of death by 50% compared to pembrolizumab alone. An interim analysis of the LiGeR-HN1 trial reported an odds ratio of 3.17 for objective response, with results remaining consistent regardless of HPV status. Genmab stated the safety profile was well tolerated with no new safety signals observed.

Further clinical successes include data from the Rina-S trial for platinum-resistant ovarian cancer, which showed a 57% reduction in the risk of death. These developments, alongside petosemtamab results in metastatic colorectal cancer, have contributed to significant increases in Genmab shares. The company plans to engage with global regulatory authorities regarding these findings.

## Claims

- The petosemtamab and pembrolizumab combination reduced the risk of death by 50% compared to pembrolizumab alone in the LiGeR-HN1 trial. (reported by 7 sources)
- The combination therapy achieved an objective response rate odds ratio of 3.17. (reported by 6 sources)
- No new safety signals were identified during the trial. (reported by 6 sources)
- Genmab plans to discuss these results with global regulatory authorities. (reported by 6 sources)
- The clinical benefits were observed regardless of HPV status. (reported by 5 sources)
- Petosemtamab is a bispecific antibody targeting EGFR and LGR5. (reported by 4 sources)
- Genmab shares rose significantly following the clinical announcements. (reported by 3 sources)
- The LiGeR-HN1 trial was a global, multicenter, randomized, open-label phase 3 trial. (reported by 2 sources)
- The Rina-S trial for ovarian cancer showed a 57% reduction in the risk of death. (reported by 1 source)

## Timeline

### 2026-10-28: Genmab petosemtamab combination reduces head and neck cancer death risk by 50%

Genmab’s Phase 3 LiGeR-HN1 trial shows that combining petosemtamab with Keytruda reduces the risk of death by 50% in patients with certain head and neck cancers.

8 sources. https://clstr.news/cluster/genmab-shares-surge-following-positive-head-and-neck-cancer-trial-results

### 2026-10-03: Genmab reports positive Phase 1/2 data for Rina-S in ovarian cancer

Genmab A/S reported a 45.9% response rate for its Rina-S drug in a Phase 1/2 trial for platinum-resistant ovarian cancer, showing activity across various folate receptor alpha expression levels.

4 sources. https://clstr.news/cluster/genmab-reports-positive-phase-12-data-for-rina-s-in-ovarian-cancer

---
Cite as: Genmab clinical trial developments. CLSTR, https://clstr.news/situations/genmab-clinical-trial-developments